Table 1 Clinical and pathologic characteristics of the study cohort

N

47

31

16

Median age at diagnosis

62

63

60

Sex

Male

24

14

10

Female

23

17

6

Race

White

44

30

14

Black

2

0

2

Hispanic

1

1

0

Treatment

Pembrolizumab

18

12

6

Nivolumab

10

4

6

Ipilimumab + nivolumab

19

15

4

Prior checkpoint blockade

Yes

16

11

5

No

31

20

11

Mutation status

BRAF

16

11

5

NRAS

6

5

1

CKIT

2

2

0

None detected

23

13

10

Stage at diagnosis

I

5

3

2

II

8

5

3

III

17

11

6

IV

11

8

3

Unknown

6

4

2